Research programme: obesity therapy - NOXXON Pharma

Drug Profile

Research programme: obesity therapy - NOXXON Pharma

Alternative Names: NOX-B11

Latest Information Update: 14 Aug 2009

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Nucleotide aptamers
  • Mechanism of Action Ghrelin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 14 Aug 2009 Preclinical development is ongoing in Germany
  • 24 Mar 2006 NOXXON Pharma and Pfizer have entered into an exclusive worldwide agreement to develop NOX-B11 for obesity
  • 12 Jul 2005 Preclinical trials in Obesity in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top